HongtaoLiuMDPhD(He/Him)

Oncology • Madison, WI

Hematologic Oncology

Director of stem cell transplant Associate Professor of Medicine University of Wisconsin at Madison

Join to view full profile

Dr. Liu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liu's full profile

Already have an account?

Office
1111 Highland Ave
WIMR1 Rm 4033
Madison, WI 53705
Phone+1 608-265-0106

Fax+1 608-234-4383

Summary

Dr. Hongtao Liu is an oncologist in Madison, WI and is affiliated with University of Wisconsin-Madison. He received his medical degree from Beijing Medical University and has been in practice 24 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hematopoietic stem cell transplantation.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2008 - 2011
Texas Tech University (Amarillo)Residency, Internal Medicine, 2005 - 2008
Beijing Medical UniversityClass of 1993

Certifications & Licensure

IL State Medical License 2007 - 2026
WI State Medical License 2023 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2013 Apr 04
Completed
Phase 2
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission Start of enrollment: 2011 Dec 05
Completed
Phase 1
Selinexor (KPT-330) in Older Patients With Relapsed AML Start of enrollment: 2014 Mar 01
Completed
Phase 2
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies Start of enrollment: 2017 Mar 20
Terminated
Phase 1
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Start of enrollment: 2020 Oct 14
Active, not recruiting
Phase 2
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Start of enrollment: 2021 Aug 20
Recruiting
Phase 1
Natural Killer Cell (CYNK-001) Infusions in Adults With AML Start of enrollment: 2020 Mar 12
Recruiting
Phase 1
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Start of enrollment: 2020 Sep 21
Active, not recruiting
Phase 1
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML Start of enrollment: 2020 Sep 14
Recruiting
Phase 1
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation Start of enrollment: 2012 Oct 16
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.
Kalyan V G Nadiminti, Kieran D Sahasrabudhe, Hongtao Liu
Journal of Hematology & Oncology. 2024-11-18
Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomes.
Koen van Besien, Hongtao Liu, Seunghee Margevicius, Pingfu Fu, Andrew Artz
Leukemia & Lymphoma. 2024-10-01
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in-mutated acute myeloid leukemia (AML) patients.
Gong He, Erika Belmont, Theodore Karrison, Wendy Stock, James L LaBelle
Annals of Translational Medicine. 2024-06-10

Abstracts/Posters

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Hongtao Liu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
Hongtao Liu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

The Immunotherapy RevolutionMay 3rd, 2017